avasimibe has been researched along with Hepatitis C, Chronic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, H; Hu, L; Li, J; Li, YP; Peng, T; Qiu, X; Xia, H; Xiao, J; Yao, W | 1 |
1 other study(ies) available for avasimibe and Hepatitis C, Chronic
| Article | Year |
|---|---|
Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Topics: Acetamides; Acetates; Antiviral Agents; Apolipoproteins B; Apolipoproteins E; Carrier Proteins; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Lipid Metabolism; Lipid Regulating Agents; RNA, Small Interfering; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Virion; Virus Assembly | 2017 |